We are joined by Alexander Perl at EHA 2019 to discuss his presentation on gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3MUT+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase III ADMIRAL trial.
Questions
1. What are the major types of FLT3 mutation and what is their impact on prognosis? (0:05)
2. What are the major challenges in the treatment of FLT3-mutated acute myeloid leukemia (AML)? (1:05)
3. What are the advantages of gilteritinib compared to existing FLT3 inhibitors? (2:14)
4. Could you tell us a little about the ADMIRAL trial and its findings? (3:30)
5. What is the potential for using gilteritinib in the first-line treatment setting? (6:33)
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
